News by subject: TRI

MemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County ? and one of only two in California ? to offer a new, innovative way to treat prostate cancer patients with water vapor. This study, VAPOR 2, utilizes a...

Seragon Biosciences, Inc. today announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was undertaken to evaluate the impact of SRN-901 on aging as well as various health...

The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Canine Cancer Awareness Month in May to highlight the impact of its funded canine cancer research. The Foundation's active cancer...

Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron (GEMTESA®) versus...

Synaptogenix, Inc. ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend...

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st ? 7th line, with median durability at 4.9 months and...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces new analyses from its Phase 2b PARADIGM clinical trial, demonstrated a statistically significant slowing of...

IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a...

Neurocrine Biosciences, Inc. today announced that it will present key information from its neuroendocrinology pipeline,...

Myrtelle Inc. ("Myrtelle" or the "Company"), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, will host a symposium on Canavan disease (CD) clinical trial updates and future...

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced that the U.S. Food and Drug Administration...

Actinium Pharmaceuticals, Inc. (NYSE...

CalciMedica Inc. ("CalciMedica") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today...

Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced multiple poster presentations at the American Society of Gene & Cell...

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced today that it has received approval from the US Food and Drug Administration (FDA) to initiate its "Pivotal Study to Evaluate...

Endo, Inc. announced today that three new presentations related to Peyronie's disease and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Urological Association (AUA) annual meeting, which took place May 3-6, 2024....

Anjarium Biosciences, a cell and gene therapy tools and technology company enabling researchers and manufacturers to accelerate the discovery and delivery cycle...

Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...

Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced study results published as a preprint on bioRXiv demonstrating the potential for Circular...

Bio-Techne Corporation today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore,...

Hopewell Therapeutics, a biotechnology company focused on discovering, synthesizing, and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to deliver genomic medicines to patients, today announced that the Company will...

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral and laser-delivered Multi-Characteristic Opsin (MCO) gene therapy platforms will be...

Dose-dependent rescue of neurological phenotypes, including epileptic seizures, motor deficits, and cognitive impairments, with long-lasting effects in adult mice Capsida poster will also show new data with its next-generation gene therapy showing...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX,...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today that China National Medical Products Administration (NMPA) has...

A new study published in MICR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MD). Titled "Examining the Efficacy of Extended Reality-Enhanced Behavioral Activation for Adults With Major...

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) ("Lykos"), a company dedicated to transforming mental healthcare, announced that on June 4, 2024, the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory...

Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania revealed a powerful new bone marrow atlas that will offer the public a first-of-its-kind visual passport into the spectrum...

Last month a new utility patent, US Patent 11,953,501, was issued to LSU Health New Orleans for a noninvasive test called NECDetect that aids in early detection of necrotizing enterocolitis (NEC), a potentially fatal condition in premature infants....

Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announced positive safety and feasibility results from its ENGULF US clinical...

CG Pharmaceuticals, a late-stage clinical biopharmaceutical company specializing in metastatic pancreatic ductal adenocarcinoma (PDAC) maintenance therapy (NCT05249101), will feature one of our investigators, Dr. Christos Fountzilas from Roswell Park...

Cytokind, Inc. is proud to announce that Professor Ahmed Z. Obeidat's abstract has been selected as a finalist for the prestigious title of the 2024 Consortium of Multiple Sclerosis Centers' "CMSC Neuroinnovator of the Year." The recognition...

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of results from the pivotal Phase 3 FOCUS study of HEPZATO KIT (melphalan/Hepatic...

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic...

Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company...

Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that an abstract has been accepted for oral presentation at the upcoming American Society of Gene & Cell Therapy 2024 (ASGCT 2024),...

Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.     The method, invented by University of Birmingham scientists and patented by University of Birmingham...

The FDA has cleared the investigational new drug (IND) application for EIS-12656, a first-in-class orally bioavailable and blood brain barrier-penetrant allosteric inhibitor of ALC1 (CHD1L), a key molecular machine in DNA repair.EIS-12656 targets...

Mediar Therapeutics,...

Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light....

Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and...

Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib...

Neurocrine Biosciences, Inc. , today presented the CAHtalysttm Pediatric Phase 3 clinical study baseline characteristics data for...

Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone...

According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer...

Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented...

Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCMtm plus offloading of weight on the...

Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that Dr. Rangasamy Ramanathan, professor of pediatrics division chief, division of...